LENZ Stock Forecast: LENZ Therapeutics, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering LENZ Therapeutics, Inc. hold a median 12-month price target of $9.5 — +196.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 18 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores LENZ Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (65): Analysts have, on balance, been raising their forecasts.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LENZ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LENZ, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +196.0% from it.
Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2026 | Citigroup | Maintains | Buy | $10 → $9.00 |
| 30 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $38 → $16 |
| 29 Oct 2026 | TD Cowen | Maintains | Buy | $50 → $45 |
| 21 Oct 2026 | TD Cowen | Maintains | Buy | $60 → $50 |
| 19 Oct 2026 | Piper Sandler | Maintains | Neutral | $7.00 → $5.00 |
| 12 Aug 2026 | Piper Sandler | Maintains | Neutral | $12 → $7.00 |
| 7 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $38 |
| 13 May 2026 | Citigroup | Maintains | Buy | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 May 2026 | Piper Sandler | Downgrade | Neutral | — |
| 21 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 20 Oct 2025 | Raymond James | Reiterates | Outperform | — |
| 10 Oct 2025 | Piper Sandler | Maintains | Overweight | — |
| 1 Aug 2025 | Citigroup | Maintains | Buy | — |
| 1 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2025 | Citigroup | Maintains | Buy | — |
| 31 July 2025 | Raymond James | Maintains | Outperform | — |
| 28 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LENZ.
This page is one stock. Monday covers all of them.
LENZ appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LENZ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 8.5×
- Price / book
- 0.5×
- EV / EBITDA
- —
Cheaper than 14% of US stocks
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 94.9%
- Operating margin
- —
- Net margin
- —
Higher than 98% of US stocks
- Return on equity
- −72.7%
- Return on assets
- −44.5%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LENZ Therapeutics, Inc. has a market value of $104.9M.
Revenue in the twelve months to 30 June 2026: $21.5M. The latest quarter grew 9.7% year on year.
Net income over the same four quarters: −$126.0M, a −586.7% net margin.
Diluted earnings per share, trailing twelve months: −$4.09.
Free cash flow in the twelve months to 30 June 2026: −$114.4M.
LENZ Therapeutics, Inc. employs 40 people — $537K of revenue per employee.
Data provided by Twelve Data
LENZ and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LENZ’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own LENZ Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LENZ
What is the LENZ stock price forecast for 2026-2027?
The 6 Wall Street analysts covering LENZ Therapeutics, Inc. have a median 12-month price target of $9.5, with estimates ranging from $4 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LENZ stock a buy right now?
Of the 6 analysts covering LENZ Therapeutics, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENZ Therapeutics, Inc. 22 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LENZ?
As at 18 Nov 2026, LENZ Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (65 of 100).
Will LENZ stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +196.0% from the last close, and Ticker Nerd's factor model ranks LENZ Therapeutics, Inc. 22 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LENZ stock forecast for 2030?
No analyst covering LENZ Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LENZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $45 over the next 12 months.
What does LENZ Therapeutics, Inc. do?
LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision.
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision. The company develops eye-care therapies designed for convenient daily use, with an emphasis on preservative-free, single-use formulations that support patient adherence and ease of administration. LENZ Therapeutics serves the prescription eye-care market and concentrates on addressing a common vision condition affecting adults worldwide. Headquartered in Solana Beach, California, the company plays a specialized role in the broader ophthalmology and biopharmaceutical sectors by bringing non-surgical treatment options to market for presbyopia management.
CEO Mr. Evert B. Schimmelpennink · 40 employees · United States · https://www.lenz-tx.com